Accession Number : ADA598880


Title :   Assessment of the Prognostic and Treatment-Predictive Performance of the Combined HOXB13:IL17BR-MGI Gene Expression Signature in the Trans-ATAC Cohort


Descriptive Note : Final rept. 1 Sep 2010-30 Nov 2013


Corporate Author : GENERAL HOSPITAL CORP BOSTON MA


Personal Author(s) : Sgroi, Dennis


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a598880.pdf


Report Date : Dec 2013


Pagination or Media Count : 28


Abstract : We compared the prognostic ability of the Breast Cancer Index (BCI), Oncotype DX Recurrence Score (RS) and IHC4 for both early and late recurrence among patients with ER+, node negative (N0) disease with the ATAC clinical trial. BCI was performed from 1102 primary tumor samples from ER+ patients were evaluated. BCI-L, IHC4 and RS had significant prognostic performance for early DR (BCO-L, p0-0002), while only BCI-L was significant for late DR (LR- X2: 7-97, p=0- 0048). For risk of early DR at 5 years, BCI-L classified 59%, 25%, and 16% of patients with 1.3%, 5.6%, and 18.1% for low, intermediate and high risk, respectively. For risk of late DR at 10 years, BCI-L classified 61%, 25%, and 14% of patients.


Descriptors :   *BREAST CANCER , *GENES , CLINICAL TRIALS , DISEASES , HIGH RATE , INDEXES , NODES , PATIENTS , RECEPTOR SITES(PHYSIOLOGY) , RISK


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE